共 50 条
Enhancing accuracy in proton therapy: The impact of geometric uncertainty models in head and neck cancer treatment
被引:0
|作者:
Zhang, Ying
[1
]
Chan, Mark Ka Heng
[2
]
机构:
[1] UCL, Dept Med Phys & Biomed Engn, London, England
[2] Univ Nebraska, Dept Radiat Oncol, Med Ctr, Omaha, NE 68118 USA
来源:
关键词:
application of anatomical modeling;
head and neck cancer;
intensity-modulated proton therapy;
robust optimization;
uncertainty management;
RADIOTHERAPY;
VOLUME;
D O I:
10.1002/mp.17698
中图分类号:
R8 [特种医学];
R445 [影像诊断学];
学科分类号:
1002 ;
100207 ;
1009 ;
摘要:
BackgroundAnatomical changes present a major source of uncertainty in head and neck (H&N) cancer treatment. Accurate modeling of these changes is important for enhancing treatment precision and supporting better outcomes.PurposeThe purpose of this study is to assess different anatomical uncertainty modeling methods in robust optimization for H&N cancer proton therapy.MethodsThis retrospective study involved five nasopharynx radiotherapy patients. We compared conventional robust optimization with anatomical robust optimization (aRO): (1) conventional robust optimization (cRO-3 mm), which used 3 mm setup shift and 3% range uncertainty. (2) aRO_AM which used three predicted images from an AM capturing systematic anatomical changes, with a 1 mm setup shift and 3% range uncertainty. (3) aRO_PM, which used three predicted images from a probability model (PM) capturing the most probable deformations, also with a 1 mm setup shift and 3% range uncertainty. We assessed weekly dose coverage of the clinical target volumes (CTVs). Normal tissue complication probability (NTCP) for grade >=$\ge$ 2 xerostomia and grade >=$\ge$ 2 dysphagia were calculated using the accumulated nominal dose (without errors).ResultsaRO_PM outperformed cRO-3 mm and aRO_AM, consistently achieving V94voxmin$_{\text{voxmin}}$ >=$\ge$ 95% for all cases across treatment weeks. Additionally, aRO_PM reduced the NTCP for grade >=$\ge$2 xerostomia by an average of 4.88 %, with a maximum reduction of 8.03%, and reduced the NTCP for grade >=$\ge$2 dysphagia by an average of 1.80%, with a maximum reduction of 4.23 %.ConclusionThe PM demonstrates potential for improving robust optimization by effectively managing anatomical uncertainties in H&N cancer proton therapy, thereby enhancing treatment effectiveness.
引用
收藏
页数:5
相关论文